Kiniksa Pharmaceuticals International (KNSA) Price to Earnings (2018 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Price to Earnings came in at 392.28 in Q2 2026, up 70.65% on a YoY basis from 229.87 in Q2 2025, and up 19.81% quarter-over-quarter from 327.42 in Q1 2026.
Powered by 
Analysis
Kiniksa Pharmaceuticals International (KNSA) Price to Earnings (2018 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has reported Price to Earnings for 9 consecutive years, with 392.28 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Price to Earnings rose 70.65% year-over-year to 392.28; the trailing twelve-month figure through Jun 2026 stood at 123.69 (down 85.55% YoY), and the FY2025 full-year result was 106.84, up 260.58% from the prior year.
- Price to Earnings rose to 392.28 in Q2 2026 per KNSA's latest filing, from 327.42 in the prior quarter.
- Across five years, Price to Earnings topped out at 443.99 in Q4 2025 and bottomed at 679.95 in Q2 2024.
- Historically, Price to Earnings has averaged 19.1 across 5 years, with a median of 21.14 in 2023.
- The sharpest annual moves came in 2023 and 2025: Price to Earnings tumbled 2313.55% in 2023, then soared 347.69% in 2025.
- Over 5 years, Price to Earnings stood at 23.6 in 2022, then slumped by 312.95% to 50.25 in 2023, then slumped by 543.47% to 323.34 in 2024, then jumped by 237.32% to 443.99 in 2025, then fell by 11.65% to 392.28 in 2026.
- According to Business Quant data, Price to Earnings over the past three periods registered 392.28, 327.42, and 443.99 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | Kiniksa Pharmaceuticals International | 6.09 Bn | 5.56 Bn | 220.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 392.28 |
| Mar 31, 2026 | 327.42 |
| Dec 31, 2025 | 443.99 |
| Sep 30, 2025 | 319.30 |
| Jun 30, 2025 | 229.87 |
| Mar 31, 2025 | 379.14 |
| Dec 31, 2024 | -323.34 |
| Sep 30, 2024 | -284.22 |
| Jun 30, 2024 | -679.95 |
| Mar 31, 2024 | -153.07 |
| Dec 31, 2023 | -50.25 |
| Sep 30, 2023 | -176.37 |
| Jun 30, 2023 | 131.97 |
| Mar 31, 2023 | -122.54 |
| Dec 31, 2022 | 23.60 |
| Sep 30, 2022 | 7.97 |
| Jun 30, 2022 | -67.36 |
| Mar 31, 2022 | -54.63 |
| Dec 31, 2021 | -36.89 |
| Sep 30, 2021 | -51.38 |